ストックスクリーナーアプリを入手
1.89
5.50%
-0.11
前日終値:
$2.00
開ける：
$2
24時間の取引高:
566.18K
Relative Volume:
1.55
時価総額：
$229.19M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.6038
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
-7.80%
1か月 パフォーマンス:
+26.00%
6か月 パフォーマンス:
-2.07%
1年 パフォーマンス:
-41.12%
1日の値動き範囲:
$1.80
$2.015
1週間の範囲:
$1.80
$2.1591
52週間の値動き範囲:
$1.33
$3.345
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
(302) 295-3800
住所
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.89 | 242.53M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - ulpravda.ru
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - Defense World
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71 - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Contrasting Inhibikase Therapeutics (NYSE:IKT) and Sorrento Therapeutics (NASDAQ:SRNE) - Defense World
Is Inhibikase Therapeutics Inc. stock a safe buy before earningsOptions Trading Strategies & Low Risk Trading Growth - bollywoodhelpline.com
Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Contrast - Defense World
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Can Inhibikase Therapeutics Inc. stock double in next 5 years2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - Улправда
Gains Report: Why Inhibikase Therapeutics Inc. stock remains a top recommendationEarnings Summary Report & Low Risk High Reward Trade Ideas - moha.gov.vn
Will Inhibikase Therapeutics Inc. stock sustain high P E ratios2025 Market Sentiment & Growth Focused Stock Reports - Улправда
Inhibikase Updates ATM Equity Program to Raise Capital - The Globe and Mail
Inhibikase Therapeutics Updates ATM Offering Program - TradingView — Track All Markets
Is Inhibikase Therapeutics Inc. stock recession proofJuly 2025 Sentiment & Safe Entry Trade Signal Reports - DonanımHaber
Why Inhibikase Therapeutics Inc. stock remains a top recommendationQuarterly Performance Summary & Momentum Based Trading Signals - DonanımHaber
Dow Update: Is Inhibikase Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & Reliable Volume Spike Alerts - Улправда
What drives Inhibikase Therapeutics Inc stock priceVolume Weighted Average Price & Free Stock Index Interpretations - earlytimes.in
While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st
Inhibikase Therapeutics Earnings Notes - Trefis
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald - MarketBeat
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT) - MarketBeat
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Zacks Research - MarketBeat
Is Inhibikase Therapeutics Inc. stock near bottom after decline2025 Earnings Surprises & Low Risk Entry Point Guides - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
How big funds are accumulating Inhibikase Therapeutics Inc. (IQT0) stockWeekly Trade Report & Risk Controlled Swing Alerts - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock benefit from mergersPortfolio Risk Summary & Real-Time Volume Trigger Notifications - Newser
Inhibikase Therapeutics, Inc. (IKT) -5.96% in After-hours: Shares Drop Amid Ongoing Offerings - Stocks Telegraph
Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair valueDollar Strength & High Yield Equity Trading Tips - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock split increase liquidityWeekly Trade Report & Weekly Breakout Watchlists - Newser
FY2025 Earnings Estimate for IKT Issued By Lifesci Capital - MarketBeat
Can Inhibikase Therapeutics Inc. stock beat market expectations this quarterTrade Entry Summary & Real-Time Buy Zone Alerts - Newser
Will Inhibikase Therapeutics Inc. stock outperform tech sector in 20252025 Market Outlook & Capital Efficient Trade Techniques - Newser
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):